FDA Extends Review of Pfizer’s Inhaled Insulin
- Share via
From Bloomberg News
Pfizer Inc. said U.S. regulators extended its review period for Exubera, an inhaled insulin treatment that could serve as an alternative to needles for 4 million American diabetics.
The Food and Drug Administration needs as long as three months to look at additional data provided by the companies, New York-based Pfizer said.
Pfizer developed Exubera, the first treatment of its type, with Nektar Therapeutics of San Carlos, Calif., and Sanofi-Aventis of Paris.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
